Cell-of-Origin Effect of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma: No Ordinary Subgroup Analysis.

David A Russler-Germain Edward Robert Scheffer Cliff Nancy L Bartlett

Published in: Blood (2023)

Subgroup analysis from the POLARIX trial of polatuzumab vedotin plus chemotherapy for untreated large B-cell lymphoma suggests greater efficacy among patients with activated B-cell subtype disease. Both preclinical and additional clinical evidence support this interaction between cell-of-origin and polatuzumab efficacy.

Keyphrases

diffuse large b cell lymphoma
cell therapy
single cell
epstein barr virus
phase iii
clinical trial
randomized controlled trial
stem cells
squamous cell carcinoma
radiation therapy
study protocol
locally advanced
mesenchymal stem cells
data analysis